Full Press Release Details
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure.
LXRX
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
Key Takeaway: Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
Price reaction · baseline $3.13 (2022-07-26 close) · hit after-hours · 2 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+4.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus